Business Overview:

Illumina, Inc. (Illumina) offers sequencing- and array-based solutions for genetic analysis. Company serves a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Illumina’s primary customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Company’s portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its portfolio addresses the range of genomic complexity, price points, and throughput, enabling customers to select the best solution for their research or clinical challenge. Illumina also provides whole-genome sequencing, genotyping, NIPT, and product support services.

For the fiscal year ended December 2017, company’s net revenue increased $354 million or 15% to $2.8 billion in 2017, as compared to the revenues in fiscal 2016. Increase in net sales was due to the growth in sales of its sequencing consumables and genotyping services, as well as the launch of its NovaSeq platform.